ANI Pharmaceuticals (NASDAQ: ANIP) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Analyst Recommendations

This is a summary of recent ratings and target prices for ANI Pharmaceuticals and Alkermes, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals 0 1 2 0 2.67
Alkermes 0 5 5 0 2.50

ANI Pharmaceuticals presently has a consensus price target of $70.33, indicating a potential upside of 1.30%. Alkermes has a consensus price target of $64.50, indicating a potential upside of 21.97%. Given Alkermes’ higher possible upside, analysts plainly believe Alkermes is more favorable than ANI Pharmaceuticals.

Valuation and Earnings

This table compares ANI Pharmaceuticals and Alkermes’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals $128.62 million 6.29 $3.93 million $0.64 108.49
Alkermes $745.69 million 10.91 -$208.44 million ($1.11) -47.64

ANI Pharmaceuticals has higher earnings, but lower revenue than Alkermes. Alkermes is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

55.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 99.7% of Alkermes shares are held by institutional investors. 31.8% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares ANI Pharmaceuticals and Alkermes’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals 4.45% 22.40% 11.14%
Alkermes -20.12% -7.27% -5.05%

Volatility & Risk

ANI Pharmaceuticals has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500.

Summary

ANI Pharmaceuticals beats Alkermes on 8 of the 13 factors compared between the two stocks.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company’s products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company’s product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.